Natalizumab vs fingolimod in patients with active relapsing-remitting multiple sclerosis (RRMS): comparative MRI assessments of disease activity from reveal, a randomized, head-to-head phase 4 study
Stephanie Licata, Helmut Butzkueven, Douglas Jeffery, Douglas L. Arnold, Massimo Filippi, Jeroen J.G. Geurts, Q. Dong, Nolan Campbell, Pei‐Ran Ho (2017). Natalizumab vs fingolimod in patients with active relapsing-remitting multiple sclerosis (RRMS): comparative MRI assessments of disease activity from reveal, a randomized, head-to-head phase 4 study. , 381, DOI: https://doi.org/10.1016/j.jns.2017.08.703.
